DE60234115D1 - Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier - Google Patents

Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier

Info

Publication number
DE60234115D1
DE60234115D1 DE60234115T DE60234115T DE60234115D1 DE 60234115 D1 DE60234115 D1 DE 60234115D1 DE 60234115 T DE60234115 T DE 60234115T DE 60234115 T DE60234115 T DE 60234115T DE 60234115 D1 DE60234115 D1 DE 60234115D1
Authority
DE
Germany
Prior art keywords
inducing
animal
human
immune response
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60234115T
Other languages
German (de)
English (en)
Inventor
Alexei Kirkin
Karine Djandjougazian
Jesper Zeuthen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enochian Biosciences Denmark ApS
Original Assignee
Dandrit Biotech AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dandrit Biotech AS filed Critical Dandrit Biotech AS
Application granted granted Critical
Publication of DE60234115D1 publication Critical patent/DE60234115D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60234115T 2001-11-29 2002-11-29 Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier Expired - Lifetime DE60234115D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200101770 2001-11-29
US33670601P 2001-12-07 2001-12-07
PCT/DK2002/000802 WO2003045427A2 (en) 2001-11-29 2002-11-29 Pharmaceutical composition for inducing an immune response in a human or animal

Publications (1)

Publication Number Publication Date
DE60234115D1 true DE60234115D1 (de) 2009-12-03

Family

ID=26069102

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60234115T Expired - Lifetime DE60234115D1 (de) 2001-11-29 2002-11-29 Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier

Country Status (11)

Country Link
US (2) US7771998B2 (https=)
EP (1) EP1448229B1 (https=)
JP (1) JP2005515192A (https=)
AT (1) ATE446106T1 (https=)
AU (1) AU2002365291B2 (https=)
DE (1) DE60234115D1 (https=)
DK (1) DK1448229T3 (https=)
ES (1) ES2335396T3 (https=)
IL (1) IL161832A0 (https=)
RU (1) RU2313365C2 (https=)
WO (1) WO2003045427A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ755300A0 (en) 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
DE10112851C1 (de) * 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
EP1565577B1 (en) * 2002-11-28 2007-09-19 Peter Kufer Novel real-time rt-pcr for the sensitive detection of multiple mage gene transcripts
EP1820856B1 (en) * 2004-11-18 2011-04-27 National University of Corporation Hiroshima University Method and kit for expressing protein under regulation of the expression from repeated sequence formed by gene amplification and transformant
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
EP1996614A1 (en) 2006-01-30 2008-12-03 The Ludwig Institute for Cancer Research Ctsp cancer-testis antigens
GB0612342D0 (en) * 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
GB0700284D0 (en) * 2007-01-08 2007-02-14 Glaxosmithkline Biolog Sa Combination therapy
EP2154243B1 (en) * 2007-05-17 2016-01-13 ID Pharma Co., Ltd. Method for production of dendritic cell
JP2011529080A (ja) * 2008-07-24 2011-12-01 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド 癌幹細胞を標的とする治療法
CN102575227A (zh) * 2008-10-08 2012-07-11 英特瑞克斯顿股份有限公司 表达多种免疫调节剂的工程改造细胞及其应用
EP3101122B1 (en) 2009-08-24 2023-06-14 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
CA2794196A1 (en) * 2010-03-23 2011-09-29 Intrexon Corporation Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
GB201013443D0 (en) * 2010-08-11 2010-09-22 Cytovac As Compositions and methods for producing dendritic cells
EP2750768B1 (en) 2011-08-30 2018-10-03 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
AU2012325758A1 (en) * 2011-10-20 2014-04-24 Neostem Oncology, Llc Antigen presenting cancer vaccine with gamma interferon
JP5871228B2 (ja) * 2011-10-31 2016-03-01 国立大学法人佐賀大学 慢性副鼻腔炎の検出方法
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
PT2812431T (pt) 2012-02-09 2019-10-18 Baylor College Medicine Pepmixes para gerar ctls multivirais com larga especifidade
WO2014007669A1 (ru) * 2012-07-04 2014-01-09 Volgushev Sergei Anatolievich Аутологичная клеточная вакцина для лечения онкологических заболеваний и способ ее получения
AU2016287585B2 (en) 2015-07-02 2020-12-17 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
JP6999941B2 (ja) 2015-09-18 2022-02-10 ベイラー カレッジ オブ メディスン 病原体からの免疫原性抗原同定および臨床的有効性との相関
GB201520542D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
KR20200035438A (ko) 2017-08-03 2020-04-03 오쓰까 세이야꾸 가부시키가이샤 약물 화합물 및 이의 정제 방법
EA202190267A1 (ru) 2018-07-15 2021-05-17 Инокиан Байофарма, Инк. Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака
EP3903811A1 (en) 2020-05-01 2021-11-03 R.G.C.C. Holdings AG Pharmaceutical composition and method for inducing an immune response
EP3981425A1 (en) 2020-10-12 2022-04-13 R.G.C.C. Holdings AG Sars-cov-2 vaccines
CA3119597C (en) 2020-10-12 2023-07-11 R.G.C.C. Holdings AG Sars-cov-2 vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443832A (en) * 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
AU2087401A (en) * 1999-12-10 2001-06-18 Epimmune, Inc. Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
US20040241176A1 (en) 2000-04-27 2004-12-02 Ap Cells. Inc. Method of producing membrane vesicles
AU2002252268B2 (en) 2001-03-09 2007-01-18 Baylor Research Institute Method of treating malignancies through induction of blood immune responses

Also Published As

Publication number Publication date
AU2002365291B2 (en) 2007-11-01
WO2003045427A3 (en) 2004-03-25
US7771998B2 (en) 2010-08-10
EP1448229B1 (en) 2009-10-21
HK1086750A1 (zh) 2006-09-29
IL161832A0 (en) 2005-11-20
ES2335396T3 (es) 2010-03-26
DK1448229T3 (da) 2010-03-08
RU2313365C2 (ru) 2007-12-27
EP1448229A2 (en) 2004-08-25
WO2003045427A2 (en) 2003-06-05
JP2005515192A (ja) 2005-05-26
ATE446106T1 (de) 2009-11-15
US20060051324A1 (en) 2006-03-09
AU2002365291A1 (en) 2003-06-10
US7723107B2 (en) 2010-05-25
US20090029457A1 (en) 2009-01-29
RU2004119548A (ru) 2005-03-27

Similar Documents

Publication Publication Date Title
DE60234115D1 (de) Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier
Baldwin et al. Rapid changes in tree leaf chemistry induced by damage: evidence for communication between plants
TR199800607T1 (xx) Dendritik h�cre uyar�c� fakt�r�.
Terzieva et al. Early pregnancy human decidua is enriched with activated, fully differentiated and pro-inflammatory gamma/delta T cells with diverse TCR repertoires
ECSP105739A (es) Anticuerpos de neutralización contra gdf-8
DE69033700D1 (de) Il-11 aus säugetier
DE69734605D1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
ES2093778T3 (es) Nuevos anticuerpos y metodos para su uso.
ES2184769T3 (es) Metodos y composiciones para microencapsulacion de antigenos para utilizar como vacunas.
NZ306653A (en) Isolated dna il-17 receptors
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
ATE255420T1 (de) Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung
Liang et al. Roles of the adenosine receptor and CD73 in the regulatory effect of γδ T cells
NZ322910A (en) Tumour vaccine containing tumour cells, some with MHC-I-haplotype on cell surface to trigger immune response, and preparation of vaccine thereof
MX2023001287A (es) Bancos universales de células t específicas de antígeno y métodos de fabricación y uso terapéutico de los mismos.
ES2165232T3 (es) Sistema terapeutico transdermico (tts) que contiene oxibutinina.
DK0952772T3 (da) Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration
Aukrust et al. Mold allergy-spores and mycelium as allergen sources.
DE69929432D1 (de) Erhöhung der immunantworten bei genetischer immunisierung durch verwendung eines chemokins
WO2001049821A3 (fr) Lignees des lymphocytes t cd4 specifiques de type th1 et procede pour leur induction ex vivo
ES2131218T3 (es) Utilizacion de anticuerpos anti-idiotipicos para evitar el rechazo hiperagudo de los injertos entre dos especies diferentes.
ATE258799T1 (de) Verwendung einer chemisch stabilisierten chloritlösung zur inhibition der antigenspezifischen immunantwort
Caserta et al. Immune responses to persistent or recurrent antigens: implications for immunological memory and immunotherapy
WO2000004918A3 (de) Mittel zur immuntherapie von tumorerkrankungen
ATE433326T1 (de) Verwendung von löslichem fgl2 als immunosuppressivum

Legal Events

Date Code Title Description
8364 No opposition during term of opposition